Mitochondrial transcription factor A (mtTFA) is a member of the HMG (high mobility group)-box protein family. We previously showed that mtTFA preferentially binds to both cisplatin-damaged and oxidatively damaged DNA. In this study, we found that expression levels of both mtTFA and the mitochondrial antioxidant protein thioredoxin2 (TRX2) are upregulated in cisplatin-resistant cell lines. In addition, TRX2 directly interacts with mtTFA and enhances its damaged DNA binding activity. The interaction between mtTFA and TRX2 requires the HMG box 1 motif of mtTFA. Furthermore, when amino acid substitutions were introduced at either C49G or C246stop, TRX2 interacted with mtTFA. However, the interaction of TRX2 with mtTFA was enhanced when both mutations (C49G and C246stop) were introduced. Binding to cisplatin-damaged DNA was similar among mutant mtTFA proteins. By contrast, binding to oxidized DNA was significantly enhanced when double mutations were introduced. These results suggest that TRX2 not only functions as an antioxidant, but also supports mtTFA functions.
Introduction
The cytotoxic action of cisplatin is believed to result from the formation of covalent adducts with DNA. We have previously reported that cisplatin-targeted sequences, such as G-stretch sequences, are more numerous in humans and gorillas than in rodents, frogs and flies (1) . Furthermore, G-stretch sequences appear much more frequently in mtDNA than in nuclear DNA. Thus, we propose that mtDNA might be the main target of cisplatin.
Reactive oxygen species (ROS) have been implicated in various pathologies (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . mtDNA is more susceptible to oxidative damage than genomic DNA because of its lack of a nucleosome structure. mtTFA is a member of the HMG-box protein family (12) , members of which stimulate transcription by binding to the D-loop region of mtDNA and function in mtDNA maintenance and repair (13, 14) . Nuclear HMG-box proteins bind preferentially to cisplatin-damaged DNA (15) (16) (17) (18) . We have previously shown that mtTFA also preferentially recognizes oxidatively damaged DNA as well as cisplatindamaged DNA (19) . The enhanced binding affinity of mtTFA for damaged DNA may suggest that mtTFA protects mtDNA from various DNA damage. Additionally, mtTFA plays an important role in apoptosis. In the present study, we found that the expression levels of both mtTFA and TRX2 are upregulated in cisplatin-resistant cells. We also investigated the physical and functional interaction between mtTFA and TRX2. We found that TRX2 directly interacts with mtTFA. Our findings suggest that TRX2 not only functions as an antioxidant defense, but also cooperatively acts to support mtTFA functions.
Materials and methods
Cell culture. Human epithelial cancer HeLa cells were cultured in Eagle's minimal essential medium containing 8% fetal bovine serum, which was purchased from Nissui Seiyaku (Tokyo, Japan). Cisplatin-resistant HeLa/CP4 cells were derived from HeLa cells as described previously (20) and were found to be 23 to 63-fold more resistant to cisplatin than their parental cells (21) . Cell lines were maintained in a 5% CO 2 atmosphere at 37˚C.
Antibodies. Anti-mtTFA was prepared as previously described (22) . Anti-TRX2 (HPA000994) antibody, anti-Flag (M2) (23) . For construction of pcDNA3-Flag-TRX2, N-terminal Flagtagged TRX2 cDNAs were ligated into a pcDNA3 vector (Invitrogen, San Diego, CA). The construction of GST-mtTFA, GST-mtTFAΔ1.2, GST-mtTFAΔ2, and GST-mtTFAΔ1 has been described previously (19) . GST-mtTFA-CC (wild-type), -GC (cysteine 49 to glycine), -CX (cysteine 246 to stop codon), and -GX (cysteine 49 to glycine and cysteine 246 to stop codon) were obtained by PCR using the following primer pairs: CC, 5'-TGGCAAGTTGTCCAAAGAAACC-3' and 5'-TTTTAACACTCCTCAGCACC-3'; GC, 5'-TGGCA AGTGGTCCAAAGAAACC-3' and 5'-TTTTAACACTCCT CAGCACC-3'; CX, 5'-TGGCAAGTTGTCCAAAGAAAC-3' and 5'-TTTTATCACTCCTCAGCACC-3'; GX, 5'-TGGCA AGTGGTCCAAAGAAACC-3' and 5'-TTTTATCACTCC TCAGCACC-3'.
Expression and purification of GST-fusion proteins.
Expression and purification of GST-fusion proteins were performed as described previously (19) . Briefly, GST fusion proteins induced by 1 mM isopropyl-ß-D-thiogalactopyranoside (Boehringer Mannheim, Mannheim, Germany) were sonicated in binding buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 120 mM NaCl, 10% glycerol, 0.5% Nonidet P-40, 1 mM DTT, and 0.5 mM PMSF), and soluble fractions were mixed with glutathione-Sepharose 4B (GE Healthcare Bio-Science). GST-fusion proteins eluted with 50 mM TrisHCl (pH 8.0) and 20 mM reduced glutathione according to the manufacturer's protocol (Pharmacia, Uppsala, Sweden) were separated in SDS 10% polyacrylamide slab gels. Gel strips containing the fractionated proteins were cut and homogenized in elution-renaturation buffer (1% Triton X-100, 20 mM HEPES pH 7.6, 1 mM EDTA, 100 mM NaCl, 2 mM DTT, 0.1 mM PMSF). The eluted proteins were dialyzed in dialysis buffer (50 mM Tris-HCl pH 7.5) using a PlusOne Mini Dialysis kit (Amersham Biosciences, Piscataway, NJ).
Co-immunoprecipitation assay. Transient transfection and immunoprecipitation assays were performed as described previously (23, 24) . Briefly, 2x10 5 HeLa cells were seeded into 35-mm tissue culture plates. The following day, cells were transfected with 1 μg of each of HA-and Flag-fused expression plasmids using SuperFect reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. At 6 h post-transfection, the cells were washed with PBS, cultured at 37˚C for 48 h in fresh medium and then lysed in buffer X containing 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 120 mM NaCl, 0.5% (v/v) Nonidet P-40 (NP-40), 10% (v/v) glycerol, 1 mM PMSF, and 1 mM DTT. The lysates were centrifuged at 21,000 x g for 10 min at 4˚C and supernatants (300 μg) were incubated for 2 h at 4˚C with anti-Flag (M2) affinity gel. Immunoprecipitated samples were washed three times with buffer X and subjected to subsequent Western blot analysis.
GST pull-down assay. Expression of TH-Flag-TRX2 and serial deletion mutants of GST-mtTFA in bacteria and GST pull-down assays were carried out as described previously (25) . GST-mtTFA or its deletion mutants immobilized on glutathione-sepharose 4B were incubated with soluble bacterial extracts containing Flag-TRX2 for 2 h at 4˚C in buffer X. Bound samples were washed three times with buffer X and subjected to Western blot analysis with anti-Flag antibody.
Western blot analysis. Whole-cell lysates and nuclear extracts were prepared as described previously (23, 26) . The indicated amounts of whole-cell lysates and nuclear extracts or immunoprecipitated samples were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene difluoride microporous membranes (Millipore, Bedford, MA, USA) using a semidry blotter. Blotted membranes were treated with 3% (w/v) skimmed milk in 10 mM Tris, 150 mM NaCl Whole-cell extracts (50 μg for mtTFA and 20 μg for TRX2) were subjected to SDS-PAGE, and Western blot analysis was done with antibodies against mtTFA, TRX2 and ß-actin (loading control). Relative intensity is shown under each blot. Gel staining with Coomassie brilliant blue (CBB) is also shown. and 0.2% (v/v) Tween-20, and incubated for 2 h at room temperature with primary antibody. The following antibodies and dilutions were used: a 1:1000 dilution of anti-mtTFA (22), a 1:1000 dilution of anti-TRX2, a 1:10,000 dilution of anti-ß-actin, and a 1:7500 dilution of anti-Flag (M2). Membranes were then incubated for 45 min at room temperature with a peroxidase-conjugated secondary antibody or a 1:5000 dilution of anti-HA-peroxidase. Bound antibody was visualized using an enhanced chemiluminescence kit (GE Healthcare Biosciences, Piscataway, NJ, USA) and membranes were exposed to Kodak X-OMAT film (Kodak, Paris, France). For the correlation assay the intensity of each signal was quantified using the NIH imaging program, version 1.63 (NIH, Bethesda, MD, USA).
Electrophoretic mobility shift assay (EMSA).
Preparation of oligonucleotides and EMSAs were performed as described previously (19) . Briefly, the following annealed 22-mer duplexes were prepared: 5'-GGTGGCCTGACXCATTCCC CAA-3' and 3'-ACCGGACTGYGTAAGGGGTTGG-5', where X=G or 8-oxo-dG and Y=A, C, G or T. Duplexes (22-mers) were end-labeled with [· -32 P]dCTP using the Klenow fragment for extension, and gel-purified. Half the volume of the labeled oligonucleotide without 8-oxo-dG was treated with 0.3 mM cisplatin at 37˚C for 12 h, and then purified by ethanol precipitation. Purified GST fusion proteins were used directly in EMSAs. Reaction mixtures contained 5% glycerol, 10 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.4 ng/μl of 32 P-labeled probe DNA and the indicated amounts of GST fusion proteins, and were mixed. Binding reactions were incubated for 5 min at room temperature. Products were analyzed on 4% polyacrylamide gels in 0.5X Tris-borate EDTA buffer using a bioimaging analyzer (BAS 2000; Fuji Photo Film, Tokyo) (19) .
Results

Both mtTFA and TRX2 are expressed in cisplatin-resistant cells.
We previously showed that p53 interacts with mtTFA and enhances the DNA binding activity of mtTFA to cisplatindamaged DNA, but inhibits its binding to oxidatively damaged DNA (22) . Cisplatin induces both DNA damage and oxidative stress in mitochondria and thioredoxin1 is upregulated in cisplatin resistant cells. Based on these previous results, we first examined the expression of mtTFA and the antioxidant protein TRX2 in cisplatin-resistant cells. The expression levels of both mtTFA and TRX2 were upregulated in cisplatinresistant cells (Fig. 1) .
Interaction of TRX2 with mtTFA. We then next investigated whether TRX2 interacts with mtTFA. As shown in Fig. 2A , mtTFA interacts with TRX2 in vivo. To confirm the association and binding site, we performed a pull-down assay using immobilized GST-fusion proteins comprising mtTFA deletion mutants and Flag-TRX2 (Fig. 2B) . This assay demonstrated that the HMG box 1 motif of mtTFA directly participates in the interaction, but that the HMG box 2 motif does not (Fig. 2C) .
Effect of TRX2 association on the binding of mtTFA to damaged DNA. We previously showed that the HMG box 1 motif possesses damaged DNA binding activity, but that the HMG box 2 motif does not (19) . The interaction of mtTFA with TRX2 may alter the damaged DNA binding activity of mtTFA. An EMSA showed that GST-mtTFA can form a specific complex with cisplatin-damaged DNA and mismatchcontaining DNA with 8-oxo dG. We observed that addition of TRX2 to the mtTFA-DNA binding reaction resulted in significant enhancement of binding of mtTFA to both cisplatindamaged DNA and oxidatively damaged DNA (Fig. 3A and B) .
mtTFA structure regulates the association with TRX2. It has been shown that mtTFA formed multimers under physiological conditions (27) . To confirm whether the interaction of TRX2 with mtTFA requires a specific structure of mtTFA, we introduced mutations at two cysteine residues, positions 49 and 246, as shown in Fig. 4A . Pull-down assays showed that two mtTFA mutants, mtTFA-GC and mtTFA-CX, interacted with TRX2 with the same affinity as wild-type mtTFA-CC. However, the association of mtTFA with TRX2 was significantly enhanced when the mtTFA-GX mutant was used (Fig. 4B ). This indicates that the cysteine-dependent secondary structure of mtTFA may regulate its association with TRX2. These mutants, as well as wild-type mtTFA, could bind to damaged DNA. Oxidized DNA binding was significantly increased when the mtTFA-GX mutant was used (Fig. 4C) . The enhancement of the DNA binding activity of mtTFA by TRX2 was observed for all mtTFA mutants (Fig. 4D ).
Discussion
In this study, we identified a novel interaction of mtTFA with TRX2. Cytosolic thioredoxin has a wide variety of biological activities (28) . Thioredoxin participates in the regulation of apoptosis via a direct interaction with ASK1 and protects cells against oxidative stress (29) . In addition to cytosolic TRX1, cells contain another TRX, TRX2, which is localized in mitochondria. Expression of the TRX1 and TRX2 genes is upregulated in cisplatin-resistant cells (30) . Nuclear HMG box proteins are often upregulated in cisplatin-resistant cells (1) . Here, we observed a significant increase in the levels of the mitochondrial HMG box protein mtTFA in cisplatinresistant cells. Collectively, these data suggest a functional interaction between mtTFA and TRX2 because both proteins are localized in mitochondria. Mitochondria act as suppliers of ATP and produce ROS. On the other hand, mitochondria function as central players in modulating apoptosis. Little is known regarding the function of TRX2 and its potential role in apoptosis (31) . It has been shown that overexpression of TRX2 makes cells resistant to etoposide (32) . Our data also reveal that TRX2 expression is upregulated in cisplatinresistant cells, consistent with the fact that drug-resistant cells often show apoptosis-resistant phenotypes. Similar results have previously been reported, such as the finding that both TRX1 and TRX2 expression are increased in doxorubicinresistant ovarian cancer cells (33) . Additionally, significantly increased levels of apoptosis have been observed in mtTFAknockout mice, suggesting that mtTFA also plays an important role in apoptosis. mtTFA functions not only as a transcription factor, but also as DNA binding protein, like nuclear chromatin, to protect mtDNA from DNA damage. Fig. 2 shows that TRX2 supports the DNA binding activity of mtTFA to damaged DNA through a direct interaction.
We previously showed that both HMG box 1 and HMG box 2 motifs could interact independently with p53, which is localized to mitochondria under conditions of DNA damage stress (34) . TRX2 interacts with the HMG box 1 motif of mtTFA (Fig. 2C) . These findings indicate that mode of interaction of TRX2 with mtTFA is completely different from that of the interaction with p53 (22) . Although there is some similarity in the primary amino acid sequences between HMG box 1 and HMG box 2, TRX2 only interacts with HMG box 1. This suggests that the secondary structure of mtTFA may modulate its association with TRX2. We then introduced mutations at two cysteine residues, positions 49 and 246 (Fig. 4A) . The mutant mtTFA proteins could bind equally well to damaged DNA as wild-type mtTFA. However, the association of TRX2 with mtTFA was enhanced when the mtTFA-GX mutant was used. TRX2 can support DNA binding by mtTFA, even when a conformational change in mtTFA is The physiological multimerization of mtTFA may efficiently support DNA binding to mtDNA. A conformational change in mtTFA might inhibit multimerization. Therefore, TRX2 can enhance the DNA binding activity of damaged mtTFA, which cannot form multimers, to protect mtDNA. Characterization of the interaction of TRX2 with mtTFA will aid our understanding of the mtTFA function in both normal and pathological conditions.
